Keros Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	87.01	-187.35	-152.99	-104.68	-58.74
Depreciation & Amortization	1.51	1.23	0.82	0.67	0.38
Stock-Based Compensation	28.7	34.87	28.76	18.68	11.72
Other Adjustments	2.4	1.82	1.56	0.95	0.57
Change in Receivables	-0.83	-2.6	-0.14	18	-18
Changes in Accounts Payable	-3	-0.25	1.61	-0.41	1.49
Changes in Accrued Expenses	-10.13	2.95	5.26	5.32	2.65
Changes in Income Taxes Payable	-2.25	-	-	-	-
Changes in Other Operating Activities	4.1	-11.54	-9.38	-8.61	-2.21
Operating Cash Flow	107.51	-160.87	-124.51	-70.06	-62.15
Capital Expenditures	-1.55	-1.93	-2.46	-1.24	-1.02
Investing Cash Flow	-1.55	-1.93	-2.46	-1.24	-1.02
Issuance of Common Stock	0.29	392.28	179.05	120.4	28.55
Repurchase of Common Stock	-375	-	-	-	-
Net Common Stock Issued (Repurchased)	-374.71	392.28	179.05	120.4	28.55
Other Financing Activities	-3.76	-0.45	-0.09	-0.09	-
Financing Cash Flow	-378.47	391.82	178.96	120.31	28.55
Net Cash Flow	-272.52	229.02	51.98	49.01	-34.62
Free Cash Flow	105.95	-162.8	-126.97	-71.3	-63.17
FCF Margin	43.41%	-4585.92%	-84087.40%	-	-314.29%
Free Cash Flow Per Share	2.80	-4.35	-4.31	-2.82	-2.71
Levered Free Cash Flow	75.69	-196.89	-157.15	-108.94	-57.46
Unlevered Free Cash Flow	59.83	-220.04	-174.1	-119.05	-53.09

Updated Mar 4, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q